A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation - Scorecard - MDSpire

A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation

  • By

  • Chenlu Hou

  • Yifan Zhang

  • Xiangqi Cao

  • Yonglan Tang

  • Ting Gao

  • Baoli Tang

  • Ying Zhu

  • Zhe Ruan

  • Ting Chang

  • June 3, 2026

  • 0 min

Share

Clinical Scorecard: Development and Validation of a Predictive Model for Low-Dose Rituximab Efficacy in Myasthenia Gravis with Anti-Acetylcholine Receptor Antibodies

At a Glance

CategoryDetail
Condition
Key MechanismsRituximab depletes B cells via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Target Population
Care Setting

Key Highlights

    Guideline-Based Recommendations

    Diagnosis

      Management

        Monitoring & Follow-up

          Risks

            Patient & Prescribing Data

            Clinical Best Practices

              Related Resources & Content

              Original Source(s)

              A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation

              • by Chenlu Hou, Yifan Zhang, Xiangqi Cao, Yonglan Tang, Ting Gao, Baoli Tang, Ying Zhu, Zhe Ruan, Ting Chang

              • June 3, 2026

              Related Content

              Mechanisms and therapeutic advances of gut metabolites in the regulation of neuroimmune inflammatory diseases

              Extracellular vesicle signalling in perioperative neurocognitive disorders

              Consensus Guidance May Improve Sinonasal Mass Outcomes

              Multidisciplinary recommendations emphasize biopsy technique, imaging, and pathology review in patients with suspected sinonasal malignancy.